AZAdam Zimilover

Adam Zimilover

*This is an algorithmically generated author record based on publicly available information.

Adam Zimilover has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Acacia Ba Sheppard

    Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

    1 shared publication
  • Alexander Shaffer

    Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA

    1 shared publication
  • Aya Haghamad

    Pathology and Laboratory Medicine, Northwell Health Laboratories, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA

    1 shared publication
  • Carly I. Hirschberg

    Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY

    1 shared publication
  • Henry Donaghy

    Northwell Health , New Hyde Park, New York

    1 shared publication
  • Iffath Islam

    Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY 10461, USA

    1 shared publication

Latest Publications

  • Open Access

    825. Cryptococcosis in the Immunocompetent Patient: Incidence and Outcomes

    by Valli Mani, Adam Zimilover, Ji-Cheng Hsieh, Maham Ghani, Simon Kashfi, Richie Chen, Iffath Islam, Henry Donaghy

    Cryptococcosis is a fungal infection that can cause pulmonary, central nervous system, or disseminated disease in immunosuppressed individuals. Although pulmonary cryptococcosis is known to rarely affect immunocompetent patients, there is limited research comparing the incidence and clinical outcomes of cryptococcosis in immunocompetent versus immunocompromised patients. A retrospective analysis was performed on patients with confirmed positive CSF PCR, CSF antigen, or serum cryptococcal antigen tests from 8 hospitals in New York from 2017-2022. Patients were classified as immunocompromised if they had HIV, an organ transplant, active cancer, or were on immunosuppressive medications at the time of diagnosis. Baseline demographic information, comorbidities, and clinical outcomes were recorded. Statistical methods performed include t-test, Chi-square, and Fisher exact test. 37 cases were identified with 9 cases (24%) in immunocompetent patients. There were no significant differences in age (p=0.82), gender (p=0.61), or BMI (p=0.15) amongst immunocompetent vs immunocompromised patients. Immunocompetent patients were more likely to have diabetes compared to immunocompromised patients (44% vs 21%, p = 0.04). Immunocompetent patients presented with meningitis more frequently (78% vs 41%, p = 0.05) with decreased mortality (11% vs 18%, p = 0.04) and no significant differences in rates of fungemia (21% vs 22%, p = 0.28). The majority of immunocompetent patients were treated inpatient and discharged on fluconazole without documented relapsed infection (77%). When assessing patients before and after 3/30/2020, the midpoint of our data timeline and beginning of the COVID pandemic, the proportion of immunocompetent cases increased (12% vs 35%, p = 0.03) while the total number of cases was relatively unchanged. Meningitis was a more common presentation than pulmonary disease in immunocompetent patients. Immunocompetent patients also had better outcomes with decreased mortality. Overall, the number of immunocompetent patients increased over the study period. Additional information about cryptococcosis in immunocompetent patients, as well as the role of diabetes and COVID infection as potential risk factors, warrants further study. All Authors: No reported disclosures

  • The clinical impact of early detection of ESBL-producing Enterobacterales with PCR-based blood culture assays

    by Kai-Ming Chang, Aya Haghamad, Patricia Saunders-Hao, Alexander Shaffer, Niloofar Mirsaidi, Adam Zimilover, Marcia Epstein, Sumeet Jain, Vincent Streva, Stefan Juretschko, et al.


  • Postpartum Aeromonas hydrophila Peritonitis and Bacteremia

    by Adam Zimilover, Taylor Do Wang, Acacia Ba Sheppard, Carly I. Hirschberg, Marcia Epstein

    Aeromonas species can be the source of severe infections in immunocompromised individuals. We present a case of a 35-year-old pregnant patient who developed postpartum septic shock and acute decompensated heart failure in the setting of Aeromonas hydrophilia peritonitis and bacteremia. Her severe presentation was thought to have occurred secondary to underlying liver dysfunction and preeclampsia. We additionally discuss the common presentations and sources of Aeromonas infections along with risk factors for severe systemic disease.

  • Open Access

    Haemophagocytic lymphohistiocytosis (HLH) in an adult following treatment with trimethoprim/sulfamethoxazole

    by Adam Zimilover, Isaac Huml

    Haemophagocytic lymphohistiocytosis (HLH) is an aggressive hyperinflammatory haematological condition often associated with malignancy, infection or rheumatological disorders. HLH has rarely been associated with medications, including antibiotics. We describe a case of a patient without significant medical history who presented with HLH following treatment with trimethoprim/sulfamethoxazole (TMP/SMX). Additionally, we will discuss the possible mechanism of medication-induced HLH as well as the successful use of dexamethasone as the sole treatment. Early diagnosis and treatment of this disease is critical and medication-induced HLH should be considered in cases without a clear aetiology. To our knowledge, this is the first case report of TMP/SMX-induced HLH that was successfully treated with steroid monotherapy and just the second case report of TMP/SMX-induced HLH.